[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centenario Hospital Miguel Hidalgo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100624098","phase-4-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-adolescents-with-early-stages-of-chronic-kidney-disease-100624098",false,"NCT07405216","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical Trial","IECA-MEX","Inclusion Criteria:Age 14-18 years\n\nResidence in Aguascalientes\n\nPersistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg)\n\nEstimated glomerular filtration rate ≥60 mL\u002Fmin\u002F1.73 m²\n\nNo identifiable secondary cause (e.g., lupus, diabetes mellitus)\n\nRenal biopsy showing adaptive podocytopathy or perihilar focal segmental glomerulosclerosis -\n\nExclusion Criteria:\n\nHypoalbuminemia\n\nNephrotic syndrome\n\nPersistent macroalbuminuria (ACR \\>300 mg\u002Fg)\n\nSecondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -","ALL","14 Years","18 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.\n\nSodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated nephroprotective effects in adult populations with CKD, including reductions in albuminuria and slowing of disease progression, independent of diabetes status. However, no randomized controlled trials have evaluated the efficacy and safety of SGLT2 inhibitors in adolescents with early-stage CKD and persistent albuminuria.\n\nThis randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether treatment with an SGLT2 inhibitor reduces albuminuria in adolescents aged 14 to 18 years with persistent microalbuminuria (albumin-to-creatinine ratio 30-300 mg\u002Fg) and preserved kidney function. Participants will be randomized in a 2:1 ratio to receive dapagliflozin 10 mg daily or placebo for six months. The primary outcome is the change in urinary albumin-to-creatinine ratio from baseline to six months. Secondary outcomes include changes in estimated glomerular filtration rate and safety outcomes.",[28,29,30,31],"Chronic Kidney Disease (Mild to Moderate)","Albuminuria","Adolescent","Sodium Glucose Co-Transporter 2 Inhibitors",[33,34,35],"Chronic kidney disease","Persistent albuminuria","sodium glucose co-transporter 2 inhibitors","RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-27","ACTUAL",{"date":42,"type":40},"2026-04-23",{"date":44,"type":22},"2027-10-30",{"name":46,"class":47},"Centenario Hospital Miguel Hidalgo","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100630132","multimodal-intervention-for-early-chronic-kidney-disease-in-young-people-dysbiosis-and-inflammation-ckd-100630132","NCT07483697","Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)","Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People: a Prospective Study","CKD","Inclusion Criteria:\n\n* Persistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg).\n* Estimated GFR \\>60 mL\u002Fmin\u002F1.73 m².\n* No identifiable secondary cause of kidney disease.\n\nExclusion Criteria:\n\n* Hypoalbuminemia.\n* Nephrotic syndrome.\n* Persistent macroalbuminuria (ACR \\>300 mg\u002Fg).\n* Secondary or hereditary kidney disease.","35 Years",{"count":21,"type":22},[60],"NA","Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.",[63,64,65,66,67,68],"Exercise","Diet Interventions","Symbiotic","CKD Stage 1","CKD Stage 3","CKD Stage 2",[55,70,71,72],"exercise","symbiotic","diet","NOT_YET_RECRUITING","2026-03-17",{"date":76,"type":40},"2026-03-19",{"date":78,"type":22},"2026-04-25",{"date":80,"type":22},"2026-11-03",{"name":46,"class":47},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100626026","synbiotic-supplementation-and-inflammation-in-predialysis-chronic-kidney-disease-100626026","NCT07430280","Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease","Effect of a Synbiotic Containing Lactobacillus Rhamnosus, Bifidobacterium Longum, and Agave Fructans on High-Sensitivity C-Reactive Protein Levels in Patients With Predialysis Chronic Kidney Disease: A Double-Blind, Placebo-Controlled Trial","SSIPCKD","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosis of chronic kidney disease in pre-dialysis stages.\n* Stable clinical condition for at least 3 months prior to enrollment.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Current renal replacement therapy (hemodialysis or peritoneal dialysis).\n* Acute kidney injury.\n* Use of antibiotics, probiotics, prebiotics, or synbiotics within 4 weeks prior to enrollment.\n* Active infection, inflammatory disease, or malignancy.\n* Pregnancy or breastfeeding\n* Known intolerance or allergy to components of the synbiotic or placebo.","80 Years",{"count":92,"type":22},100,[60],"Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. People with chronic kidney disease (CKD) often experience chronic inflammation and digestive symptoms that may affect their quality of life.\n\nThis study aims to evaluate whether daily supplementation with a synbiotic (a combination of probiotics and prebiotics) can reduce inflammation and improve gastrointestinal symptoms in adults with chronic kidney disease (CKD) stages 3 to 5 who are not receiving dialysis.\n\nParticipants will be randomly assigned to receive either a synbiotic containing Lactobacillus rhamnosus, Bifidobacterium longum, and agave fructans, or a placebo, for a total of 16 weeks. Blood tests will be performed to measure inflammation, and participants will complete questionnaires related to digestive symptoms, quality of life, and dietary habits.\n\nThe information obtained from this study may help improve nutritional strategies and supportive care for people living with chronic kidney disease.",[96,97],"Chronic Kidney Disease","Inflammation",[99,100,101,102],"Synbiotic","Gut microbiota","Predialysis","Nutrition intervention","2026-02-24",{"date":105,"type":40},"2026-02-27",{"date":107,"type":22},"2026-03-01",{"date":109,"type":22},"2026-06-01",{"name":46,"class":47},""]